Reboot Pain (tDCS)
RecruitingNot applicableNCT07411859
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will examine the effectiveness of tDCS (Transcranial Direct Current Stimulation) in reducing chronic pain when used with Emory Healthcare Veterans Program (EHVP)-ABHP (Accelerated Behavioral Health Program) participants as measured by the Pain, Enjoyment of Life and General Activity Scale (PEG).
Study details
- Official title
- Reboot Pain: Integrating Neuromodulation Into Clinical Care for Military and Veterans With Chronic Pain
- Conditions
- Interventions
- Sponsor
- Emory University
- Start date
- 2026-02-16
- Primary completion
- 2027-05
- Sex
- All
- Age range
- from 18 Years to 89 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or Female, 18-89 years old * Treated on site for ABHP * Willing to self-administer tDCS and complete the measures * PEG pain intensity of 4 or more for most of the day at least 3 days per week * Have an established PCP (Primary Care Provider) or pain management provider Exclusion Criteria: * Implanted pacemaker * Seizure Disorder * Pregnancy, if applicable * Any new onset of the following: * Balance Problems * Difficulty walking * Bladder incontinence * Bowel incontinence * Numbness * Tingling * Weakness * Medical contraindications * Current use of sodium channel blockers * Lidocaine (OTC/transdermal delivery is ok) * Mexiletine * Amitriptyline; other tricyclic antidepressants * Anti-epileptic medications: phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate * Current use of calcium channel blockers * Current use of N-Methyl-D-aspartate receptor antagonists * Ketamine * Dextromethorphan * Felbamate * History of brain surgery * History of brain tumor * History of seizure disorder * History of stroke * Intracranial metal implantation * Adults unable to consent * Individuals who are not yet adults * Prisoners * Non-English speaking
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07411859